Results 201 to 210 of about 145,099 (296)
Notch2, a Key Player in Chronic Lymphocytic Leukemia: Mechanism, Microenvironment Interactions, and Therapeutic Implications. [PDF]
Miserendino R +4 more
europepmc +1 more source
A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen +5 more
wiley +1 more source
Neutrophils unveiled in chronic lymphocytic leukemia. [PDF]
McManus S, Khare P, Bertilaccio MTS.
europepmc +1 more source
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley +1 more source
Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]
Morelli F +5 more
europepmc +1 more source
HAT‐PCR is non‐inferior to NGS when quantifying measurable residual disease for myeloma
British Journal of Haematology, EarlyView.
Elizabeth Hughes +5 more
wiley +1 more source
Postoperative Care and Management in Pediatric Hematology‐Oncology Patients
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley +1 more source
Case Report: Simultaneous chronic lymphocytic leukemia and macrofocal multiple myeloma with extramedullary plasmacytoma. [PDF]
Jin Y, Wang S, Fang Z, Qian S.
europepmc +1 more source
ABSTRACT Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence.
Nadine Kutsch +16 more
wiley +1 more source

